Skip to main content

Table 4 Change of laboratory data

From: Improvement of microcirculatory impairment in patients with predialysis chronic kidney disease after AST-120 administration

Month

-3

0

3

6

12

Fibninogen (mg/dL)

295.0 ± 66.1

296.8 ± 71.3

301.9 ± 79.9

304.2 ± 75.4

318.9 ± 62.1*

CRP (mg/dL)

0.1 ± 0.1

0.1 ± 0.3

0.3 ± 0.8

0.3 ± 0.9

0.5 ± 1.0

Albumin (g/dL)

3.9 ± 0.3

3.9 ± 0.3

3.9 ± 0.4

4.0 ± 0.3

3.9 ± 0.3

HOMA-IR

7.5 ± 11.8

6.6 ± 7.2

7.7 ± 10.5

8.6 ± 12.8

8.8 ± 15.0

T.cho (mg/dL)

186.7 ± 32.6

187.0 ± 29.3

183.3 ± 30.0

186.1 ± 32.0

186.4 ± 26.6

TG (mg/dL)

194.3 ± 133.5

217.0 ± 227.4

175.9 ± 96.9

177.9 ± 112.9

208.1 ± 196.8

HDL-C (mg/dL)

48.5 ± 11.5

50.4 ± 12.6

50.3 ± 12.2

50.9 ± 12.3

52.3 ± 12.9

LDL-C (mg/dL)

99.0 ± 30.6

96.9 ± 26.2

97.9 ± 27.9

98.6 ± 30.4

97.6 ± 27.4

Ca (mg/dL)

9.0 ± 0.4

8.9 ± 0.5

8.9 ± 0.4

8.9 ± 0.5

8.8 ± 0.5

Pi (mg/dL)

3.3 ± 0.6

3.3 ± 0.7

3.4 ± 0.7

3.3 ± 0.7

3.6 ± 0.9*

CaxPi (mg2/dL2)

29.8 ± 5.2

29.2 ± 6.4

30.4 ± 6.2

29.6 ± 5.8

31.7 ± 7.5*

  1. CRP C-reactive protein, HOMA-IR homeostasis model assessment insulin resistance, T.cho total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Ca calcium, Pi inorganic phosphate
  2. *p < 0.05 vs. 0 month